Critical Survey: IHS Markit (INFO) and The Competition

IHS Markit (NASDAQ: INFO) is one of 44 public companies in the “Computer programming, data processing, & other computer related” industry, but how does it weigh in compared to its rivals? We will compare IHS Markit to similar companies based on the strength of its valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Institutional & Insider Ownership

How to Become a New Pot Stock Millionaire

97.1% of IHS Markit shares are held by institutional investors. Comparatively, 47.5% of shares of all “Computer programming, data processing, & other computer related” companies are held by institutional investors. 2.7% of IHS Markit shares are held by insiders. Comparatively, 17.5% of shares of all “Computer programming, data processing, & other computer related” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares IHS Markit and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IHS Markit 16.06% 9.33% 5.12%
IHS Markit Competitors -15.70% -46.65% -1.75%

Analyst Ratings

This is a summary of current ratings and price targets for IHS Markit and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IHS Markit 1 2 9 0 2.67
IHS Markit Competitors 506 1896 4605 226 2.63

IHS Markit presently has a consensus price target of $52.00, suggesting a potential upside of 8.18%. As a group, “Computer programming, data processing, & other computer related” companies have a potential upside of 12.26%. Given IHS Markit’s rivals higher probable upside, analysts plainly believe IHS Markit has less favorable growth aspects than its rivals.

Risk & Volatility

IHS Markit has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, IHS Markit’s rivals have a beta of 1.41, meaning that their average stock price is 41% more volatile than the S&P 500.

Earnings and Valuation

This table compares IHS Markit and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
IHS Markit $3.60 billion $416.90 million 28.61
IHS Markit Competitors $6.96 billion $966.00 million 37.81

IHS Markit’s rivals have higher revenue and earnings than IHS Markit. IHS Markit is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

IHS Markit rivals beat IHS Markit on 7 of the 13 factors compared.

About IHS Markit

IHS Markit Ltd., formerly Markit Ltd., is a provider of critical information and analytics for the major industries, financial markets and governments. The Company operates through four segments: Resources, Transportation, Consolidated Markets & Solutions (CMS) and Financial Services. The Resources segment includes its energy and chemicals product offerings. Its energy offerings are focused on upstream, midstream, downstream and power/gas/coal/renewables (PGCR) services. The Transportation segment includes its aerospace, defense and security (AD&S); automotive, and maritime and trade (M&T) product offerings. The CMS segment includes its product design; technology, media and telecommunication, and economics and country risk (ECR) product offerings. The Company’s Financial Services segment provides pricing and reference data, indices, valuation and trading services, trade processing, enterprise software and managed services.

Receive News & Ratings for IHS Markit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IHS Markit and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Cantor Fitzgerald Raises Intuitive Surgical  Price Target to $510.00
Cantor Fitzgerald Raises Intuitive Surgical Price Target to $510.00
JPMorgan Chase Boosts UnitedHealth Group  Price Target to $266.00
JPMorgan Chase Boosts UnitedHealth Group Price Target to $266.00
Mizuho Reaffirms “Buy” Rating for QUALCOMM
Mizuho Reaffirms “Buy” Rating for QUALCOMM
Noah  and PJT Partners  Critical Review
Noah and PJT Partners Critical Review
Head-To-Head Analysis: The Meet Group  & Quotient Technology
Head-To-Head Analysis: The Meet Group & Quotient Technology
Mersana Therapeutics  Stock Rating Upgraded by Zacks Investment Research
Mersana Therapeutics Stock Rating Upgraded by Zacks Investment Research


Leave a Reply

© 2006-2018 Ticker Report. Google+.